WallStreetZenWallStreetZen

NASDAQ: AEZS
Aeterna Zentaris Inc Stock

$1.95-0.01 (-0.51%)
Updated Apr 19, 2024
AEZS Price
$1.95
Fair Value Price
N/A
Market Cap
$9.47M
52 Week Low
$1.36
52 Week High
$3.38
P/E
-0.57x
P/B
0.52x
P/S
2.01x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.50M
Earnings
-$16.55M
Gross Margin
95.1%
Operating Margin
-367.99%
Profit Margin
-368%
Debt to Equity
1.03
Operating Cash Flow
-$17M
Beta
1.01
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

AEZS Overview

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AEZS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AEZS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AEZS is good value based on its book value relative to its share price (0.52x), compared to the US Biotechnology industry average (5.74x)
P/B vs Industry Valuation
AEZS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AEZS due diligence checks available for Premium users.

Be the first to know about important AEZS news, forecast changes, insider trades & much more!

AEZS News

Valuation

AEZS fair value

Fair Value of AEZS stock based on Discounted Cash Flow (DCF)
Price
$1.95
Fair Value
-$1.95
Undervalued by
200.02%
AEZS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AEZS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.57x
Industry
15.81x
Market
40.51x

AEZS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.52x
Industry
5.74x
AEZS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AEZS's financial health

Profit margin

Revenue
$121.0k
Net Income
-$5.6M
Profit Margin
-4,657%
AEZS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AEZS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$37.0M
Liabilities
$18.8M
Debt to equity
1.03
AEZS's short-term assets ($36.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AEZS's short-term assets ($36.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AEZS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AEZS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$5.4M
Investing
$543.0k
Financing
-$38.0k
AEZS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AEZS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
AEZS$9.47M-0.36%-0.57x0.52x
CYCN$9.49M+8.76%-1.56x0.84x
BCDA$9.62M-4.51%-0.65x-6.00x
CMMB$9.66M-2.86%-0.33x0.57x
BRTX$9.27M-4.86%-0.40x0.80x

Aeterna Zentaris Stock FAQ

What is Aeterna Zentaris's quote symbol?

(NASDAQ: AEZS) Aeterna Zentaris trades on the NASDAQ under the ticker symbol AEZS. Aeterna Zentaris stock quotes can also be displayed as NASDAQ: AEZS.

If you're new to stock investing, here's how to buy Aeterna Zentaris stock.

What is the 52 week high and low for Aeterna Zentaris (NASDAQ: AEZS)?

(NASDAQ: AEZS) Aeterna Zentaris's 52-week high was $3.38, and its 52-week low was $1.36. It is currently -42.31% from its 52-week high and 43.38% from its 52-week low.

How much is Aeterna Zentaris stock worth today?

(NASDAQ: AEZS) Aeterna Zentaris currently has 4,855,876 outstanding shares. With Aeterna Zentaris stock trading at $1.95 per share, the total value of Aeterna Zentaris stock (market capitalization) is $9.47M.

Aeterna Zentaris stock was originally listed at a price of $159,450.00 in May 10, 2000. If you had invested in Aeterna Zentaris stock at $159,450.00, your return over the last 23 years would have been -100%, for an annualized return of -38.85% (not including any dividends or dividend reinvestments).

How much is Aeterna Zentaris's stock price per share?

(NASDAQ: AEZS) Aeterna Zentaris stock price per share is $1.95 today (as of Apr 19, 2024).

What is Aeterna Zentaris's Market Cap?

(NASDAQ: AEZS) Aeterna Zentaris's market cap is $9.47M, as of Apr 21, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aeterna Zentaris's market cap is calculated by multiplying AEZS's current stock price of $1.95 by AEZS's total outstanding shares of 4,855,876.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.